Kisqali 400 MG daily dose UU 42S
Ended Awarded Last action
- Contract number
- SPE2DR26FM3MG
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,098
Award facts
- Contract value 100% obligated
- $49,098.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $49,098 to AmerisourceBergen Drug Corp for the supply of Kisqali 400 mg daily dose in a quantity of 42 units. The award, made on January 29, 2026, is structured as a firm fixed-price contract with an ultimate completion date of February 20, 2026. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Kisqali is an oncology medication used in breast cancer treatment, reflecting the pharmaceutical distribution scope typical of AmerisourceBergen's federal healthcare supply portfolio.
This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 2026. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), maintains an even larger IDC with the Defense Logistics Agency valued at up to $999,999,999 through December 31, 2031, which serves as a comprehensive global pharmaceutical support vehicle enabling the supply of specialty medications, brand-name and generic drugs, vaccines, and medical supplies to military healthcare programs worldwide. AmerisourceBergen's substantial federal contract portfolio demonstrates its established capability to efficiently fulfill critical pharmaceutical procurement requirements for military treatment facilities and other federal medical institutions.
Quick answers
Who was awarded contract SPE2DR26FM3MG?
SPE2DR26FM3MG was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FM3MG worth?
The government has obligated $49,098 on SPE2DR26FM3MG.
Is contract SPE2DR26FM3MG an order under another contract?
Yes. SPE2DR26FM3MG is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM3MG competed?
The extent of competition for SPE2DR26FM3MG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award